Ethos Technologies Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Peter George Colis
- Full Time Employees
- 614
- Sector
- Financial Services
- Industry
- Insurance - Life
- Address
- 90 New Montgomery Street San Francisco CA United States of America 94105
- IPO Date
- Jan 30, 2026
- CIK
- 0001788451
- Website
- ethos.com
- Similar Companies
- Business
- aTyr Pharma, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of medicines based on novel biological pathways with a focus on tRNA synthetase biology. The company develops protein-based therapeutics targeting fibrosis and inflammation, primarily through its lead product candidate efzofitimod (ATYR1923), a first-in-class biologic immunomodulator that selectively modulates neuropilin-2 (NRP2) to resolve aberrant inflammation and potentially prevent fibrosis progression, particularly for interstitial lung diseases such as pulmonary sarcoidosis. Additional product candidates include fusion proteins derived from domains of aspartyl-tRNA synthetase (ATYR0101) and alanyl-tRNA synthetase (ATYR0750), with the latter being a novel ligand for fibroblast growth factor receptor 4 (FGFR4). The company also engages in collaborations and license agreements, notably with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod in Japan, expanding its reach in Asian markets. Founded in 2005 and headquartered in San Diego, California, aTyr Pharma is advancing its drug pipeline through clinical trials and strategic partnerships. Recently, aTyr Pharma experienced a setback when its global pivotal Phase 3 EFZO-FIT study in pulmonary sarcoidosis failed to meet the primary endpoint related to the reduction in mean daily oral corticosteroid dose at week 48. Following these results announced in September 2025, the company initiated discussions with the FDA to determine the path forward. Despite this, aTyr continues to raise capital, having secured approximately $18.8 million subsequent to Q4 2024, and maintains ongoing collaborations and research efforts, including partnerships valued at $50 million in 2023 with biotech firms and academic institutions. The company’s strategic focus remains on advancing its therapeutic candidates, expanding patient-centric clinical programs, and leveraging collaborative alliances to enhance its portfolio and geographic presence in North America, Europe, and Asia.
Gold Terra Announces Closing of First Tranche of C$10.8M LIFE Offering With Strong Participation From Strategic Shareholder David Harquail
Argyle Announces Commencement of New LIFE Offering
GLOBE LIFE INC. REPORTS SECOND QUARTER 2026 RESULTS
Ethos and North American Expand Their Indexed Universal Life Product Offering to include Children
Gamma Announces $2.1 Million LIFE Private Placement Offering
DICK'S EXPANDS ITS INVESTMENT IN WOMEN'S SPORTS WITH COOKIE JAR & A DREAM STUDIOS' "LIFE IN THE W" DOCUMENTARY SERIES ON ESPN
Graycliff Closes First Tranche of LIFE Financing
Visionstate to Pause LIFE Offering and Re-Examine Financing Approach
The Precision Peptide Company Inc. Announces Closing of LIFE Offering of Common Shares
Vortex Energy Corp. Announces Closing of LIFE Offering
Primary Hydrogen Announces Closing of LIFE Offering
Americore Announces Closing of First Tranche of LIFE Offering
Ethos to Announce Second Quarter 2026 Financial Results on August 3, 2026
Vortex Energy Corp. Announces LIFE Offering
Americore Announces Update to LIFE Offering
Coppernico Metals Closes $5.5 Million LIFE Offering
Aduro Clean Technologies Announces Closing of LIFE Offering
Primary Hydrogen Announces Amended and Restated LIFE Offering
Coppernico Metals Announces Upsized LIFE Offering
Onco-Innovations Announces Non-Brokered LIFE Offering